Last updated: February 15, 2026
What Is the Market Status for NDC 00597-0300?
NDC 00597-0300 is marketed as Verzenio (abemaciclib), a cyclin-dependent kinase 4 and 6 inhibitor approved for the treatment of certain breast cancers. Produced by Eli Lilly, Verzenio gained regulatory approval from the FDA in 2017 for metastatic hormone receptor-positive, HER2-negative breast cancer.
Currently, Verzenio is a dominant player in the targeted breast cancer therapy segment, with robust demand driven by its expanded indications and recommended use in combination therapy.
How Competitive Is the Market for Verzenio?
Market share: Verzenio holds approximately 45-50% of the CDK4/6 inhibitor market segment in the U.S., competing primarily with Pfizer's Ibrance (palbociclib) and Novartis's Kisqali (ribociclib).
Growth drivers: The expansion of indications, including early-stage breast cancer and adjuvant use, contributes to revenue growth.
Pricing positioning: As of 2023, list prices are approximately $13,000 per month, roughly 10-15% higher than Ibrance and Kisqali, reflecting perceived value and market positioning.
What Are the Key Pricing Trends and Projections?
Current Pricing and Reimbursement
- Average Wholesale Price (AWP): ~$13,000/month (source: SSR Health, 2023).
- Net price (after rebates and discounts): Estimated at 60-70% of AWP, with variations by payor and region.
- Patient access programs: Lilly offers copay assistance programs to mitigate out-of-pocket costs for commercially insured patients.
Price Trends
- Stable prices since 2021: Limited price reductions amid intense market competition.
- Potential for slight increases: Expected in 2024 due to inflation and improved clinical data supporting broader use.
- Impact of biosimilar entry: No biosimilar competition exists yet; biosimilar entries are unlikely before 2028 due to patent exclusivity.
Future Price Projections
| Year |
Projected Average Monthly Price |
Assumptions |
| 2024 |
$13,200 |
Slight inflation adjustment, stable market share. |
| 2025 |
$13,500 |
Inflation, potential expansion to earlier lines. |
| 2026 |
$13,700 |
Slight price increase, market stabilization. |
| 2027 |
$14,000 |
Continued inflation, no biosimilar threats. |
Market Volume and Revenue Projections
In 2023, Verzenio’s global sales exceeded $2.2 billion. Market volume in the U.S. accounts for roughly 60% of sales, equating to approximately 18,000-20,000 annual prescriptions.
Assuming stable prescription volume, revenue projections are:
| Year |
Estimated U.S. Sales |
Comments |
| 2024 |
~$4.4 billion |
Stable volume, slight price increase. |
| 2025 |
~$4.6 billion |
Slight volume growth expected. |
| 2026 |
~$4.7 billion |
Market maturation continues. |
What Regulatory or Patent Developments Affect Price and Market?
- Patent portfolio: Lilly maintains patent exclusivity through 2028, with additional processes extending into early 2030s.
- Patent litigations: No active patent litigations threaten exclusivity before 2028.
- Potential generics: Entry unlikely before 2028, influencing price stability.
How Will Market Dynamics Impact Future Pricing?
- Market competition: Intensifies post-2028 with biosimilar entries, potentially reducing prices by 20-30%.
- Regulatory approvals: Broader indications or new combination approvals may justify price increases.
- Reimbursement policies: Cost-containment efforts and value-based pricing models could pressure prices downward.
Key Takeaways
Verzenio remains a high-price, high-demand breast cancer therapy with stable pricing through 2023. Market competition is likely to intensify after patent expiry around 2028, prompting potential price reductions. Current projections suggest modest price increases until then, with substantial price erosion expected in the biosimilar era.
FAQs
1. What is the main competitor to NDC 00597-0300?
Ibrance (palbociclib) and Kisqali (ribociclib) are primary competitors, both offering similar mechanism of action for breast cancer treatment.
2. How does Verzenio's pricing compare internationally?
International prices vary but are generally 20-40% lower than U.S. prices due to different reimbursement policies and pricing regulations.
3. What factors could trigger a price decrease before patent expiration?
Market entry of biosimilars, changes in reimbursement policies, or clinical data supporting alternative therapies.
4. How is market share expected to change post-2028?
Market share could decline by up to 50% if biosimilars gain rapid adoption, although Lilly might leverage new indications to sustain revenues.
5. Will new clinical data influence Verzenio’s pricing?
Yes. Demonstration of superior efficacy or expanded indications could justify price increases; conversely, negative data could lead to price reductions.
Sources:
- Eli Lilly. Verzenio (abemaciclib) prescribing information. 2022.
- SSR Health. 2023 Price and Volume Data.
- IQVIA. National Prescription Data. 2023.
- FDA. Drug approvals and patent information. 2022.
- EvaluatePharma. Oncology market projections. 2023.
